
    
      OBJECTIVES: I. Determine the effectiveness and safety of epoetin alfa in patients receiving
      adjuvant chemotherapy for stage I, II, or III breast cancer. II. Determine the clinical
      outcomes in these patients receiving this drug.

      OUTLINE: This is a multicenter study. Patients receive epoetin alfa subcutaneously once
      weekly for up to 24 weeks in the absence of unacceptable toxicity. Quality of life is
      assessed at baseline, at week 13, and at study completion.

      PROJECTED ACCRUAL: A maximum of 2,500 patients will be accrued for this study.
    
  